Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Crnic Institute Human Trisome Project Biobank (HTP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02864108
Recruitment Status : Recruiting
First Posted : August 11, 2016
Last Update Posted : February 6, 2019
Sponsor:
Collaborator:
Linda Crnic Institute for Down Syndrome
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
The Human Trisome Project will significantly increase the speed of Down syndrome research and the understanding of associated medical conditions. Its biobank will provide de-identified samples to research.

Condition or disease
Down Syndrome Trisomy 21

Detailed Description:

The purpose of this study is to provide qualified and approved researchers with access to biological samples and health information to answer specific research questions. This project will significantly increase the speed of Down syndrome research and the understanding of associated medical conditions such as Alzheimer's disease, congenital heart defects, autoimmune disorders, autism, and some forms of leukemia.

Participation includes a blood draw, a mouth swab, and allowing researchers to look at your health information yearly for the next 5 years. Optional procedures include providing a urine and/or stool sample and taking part in the study for a longer time frame.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 1500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Research to Develop the Human Trisome Project Biobank
Study Start Date : July 2016
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Down Syndrome

Group/Cohort
Those with trisomy 21
People aged 6 months to 89 years old who have some form of trisomy 21.
Controls
People aged 6 months to 89 years old who do not have trisomy 21. These persons can be related to someone with some form of trisomy 21 but do not have to be related.



Primary Outcome Measures :
  1. Number of Participants and Controls Enrolled in Biobank [ Time Frame: 5 years ]
    Create biobank of blood cells and plasma, saliva, mouth swab, urine, stool, and induced pluripotent stem cells (iPSC) cells for use in approved research projects.


Secondary Outcome Measures :
  1. Number of Clinical Records Available for Approved Research Purposes [ Time Frame: 5 years ]
    Create a database of clinical information to pair with biological samples listed above.

  2. Multidimensional Sample Characterization [ Time Frame: 5 years ]
    Characterize biological samples with multidimensional cellular and molecular analyses to generate the most thoroughly characterized set of samples from individuals with Down syndrome in the world.


Biospecimen Retention:   Samples With DNA
blood, saliva, mouth swab, urine (optional), stool (optional)


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Months to 89 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Individuals with Down syndrome, individuals related to someone with Down syndrome or of the general population who do not have a relationship to Down syndrome.
Criteria

Inclusion Criteria:

Anyone 6 months to 89 years old who:

  1. has Down syndrome (any type)
  2. does not have Down syndrome

Exclusion Criteria:

  1. Prisoners
  2. Wards of the state

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02864108


Contacts
Layout table for location contacts
Contact: Angela Rachubinski, PhD (303) 724-7366 HTP@ucdenver.edu
Contact: Belinda Enriquez Estrada, BS (303) 724-0491 HTP@ucdenver.edu

Locations
Layout table for location information
United States, Colorado
Linda Crnic Institute for Down Syndrome at the University of Colorado Denver Recruiting
Denver, Colorado, United States, 80045
Principal Investigator: Joaquin Espinosa, PhD         
Sponsors and Collaborators
University of Colorado, Denver
Linda Crnic Institute for Down Syndrome
Investigators
Layout table for investigator information
Principal Investigator: Joaquin Espinosa, PhD Linda Crnic Institute for Down Syndrome at the University of Colorado Denver

Additional Information:
Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT02864108     History of Changes
Other Study ID Numbers: 15-2170
UL1TR001082 ( U.S. NIH Grant/Contract )
First Posted: August 11, 2016    Key Record Dates
Last Update Posted: February 6, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Down Syndrome
Trisomy
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Aneuploidy
Chromosome Aberrations
Pathologic Processes
Chromosome Duplication